These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 23775580

  • 21. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
    Wieringa A, Boslooper K, Hoogendoorn M, Joosten P, Beerden T, Storm H, Kibbelaar RE, Veldhuis GJ, van Kamp H, van Rees B, Kluin-Nelemans HC, Veeger NJ, van Roon EN.
    Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
    [Abstract] [Full Text] [Related]

  • 22. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.
    J Clin Oncol; 2011 Apr 10; 29(11):1452-7. PubMed ID: 21383296
    [Abstract] [Full Text] [Related]

  • 23. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
    Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD.
    Cancer; 2002 Jun 15; 94(12):3083-8. PubMed ID: 12115338
    [Abstract] [Full Text] [Related]

  • 24. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group.
    Ann Hematol; 2006 Apr 15; 85(4):257-62. PubMed ID: 16416337
    [Abstract] [Full Text] [Related]

  • 25. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.
    Eur J Haematol; 2014 Mar 15; 92(3):204-10. PubMed ID: 24283206
    [Abstract] [Full Text] [Related]

  • 26. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era.
    Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B.
    Ann Hematol; 2014 Aug 15; 93(8):1305-12. PubMed ID: 24590536
    [Abstract] [Full Text] [Related]

  • 27. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.
    Int J Oncol; 2011 Dec 15; 39(6):1413-20. PubMed ID: 21874232
    [Abstract] [Full Text] [Related]

  • 28. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X, Xia B, Guo S, Zhan Z, Zhang L, Zhao D, Wu X, Zhang Y.
    Ann Hematol; 2013 Jun 15; 92(6):807-15. PubMed ID: 23417758
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, Coiffier B, Salles G.
    Arch Immunol Ther Exp (Warsz); 2010 Apr 15; 58(2):131-41. PubMed ID: 20191326
    [Abstract] [Full Text] [Related]

  • 31. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):569-77. PubMed ID: 23540349
    [Abstract] [Full Text] [Related]

  • 32. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
    Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K.
    Ann Hematol; 2010 Sep 01; 89(9):897-904. PubMed ID: 20414658
    [Abstract] [Full Text] [Related]

  • 33. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Yan-Li L, Kang-Sheng G, Yue-Yin P, Yang J, Zhi-Min Z.
    Leuk Res; 2014 Mar 01; 38(3):323-8. PubMed ID: 24439567
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ.
    J Clin Oncol; 2016 Sep 10; 34(26):3150-6. PubMed ID: 27382100
    [Abstract] [Full Text] [Related]

  • 36. CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.
    Mitrovic Z, Ilic I, Nola M, Aurer I, Sonicki Z, Basic-Kinda S, Radman I, Ajdukovic R, Labar B.
    Clin Lymphoma Myeloma; 2009 Apr 10; 9(2):133-7. PubMed ID: 19406723
    [Abstract] [Full Text] [Related]

  • 37. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, Bar-Shalom R.
    Am J Hematol; 2013 May 10; 88(5):400-5. PubMed ID: 23423884
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.